# EDGAR Filing Document

**Accession Number:** 0001851194
**File Stem:** 0001193125-26-090533
**Filing Date:** 2026-3
**Character Count:** 8995
**Document Hash:** ff83d20f439d2f64ef8937c0efb118ba
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-090533.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001193125-26-090533

**CONFORMED SUBMISSION TYPE**: POS AM

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ventyx Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001851194
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832996852
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** POS AM
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-278584
- **FILM NUMBER:** 26719751

**BUSINESS ADDRESS:**
- **STREET 1:** 12790 EL CAMINO REAL, SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 7604076511

**MAIL ADDRESS:**
- **STREET 1:** 12790 EL CAMINO REAL, SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**As filed with the Securities and Exchange Commission on March 4, 2026** 

**Registration No. 333-278584** 

**Registration No. 333-283076** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-278584** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-283076** 

**FORM S-3** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Ventyx Biosciences, Inc.
**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **83-2996852** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**Eli Lilly and Company Global Headquarters** 

**Lilly Corporate Center** 

**Indianapolis, Indiana 46285** 

**(317) 276-2000** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Jonathan R. Haug** 

**President** 

**Ventyx Biosciences, Inc.** 

**Eli Lilly and Company Global Headquarters** 

**Lilly Corporate Center** 

**Indianapolis, Indiana 46285** 

**(317) 276-2000** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

***Copy to:***

**Emily Oldshue** 

**Michael D. Beauvais** 

**Ropes & Gray LLP** 

**Prudential Tower, 800 Boylston Street** 

**Boston, Massachusetts 02199** 

**(617) 951-7000** 

**(Approximate date of commencement of proposed sale to the public): Not applicable.** 

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**DEREGISTRATION OF SECURITIES** 

These Post-Effective Amendments (these "Post-Effective Amendments") are being filed by Ventyx Biosciences, Inc. (the "Registrant") to deregister any and all securities, registered but unsold or otherwise unissued as of the date hereof under the following Registration Statements on Form S-3 (each, a "Registration Statement", and collectively, the "Registration Statements") previously filed by the Registrant with the U.S. Securities and Exchange Commission (the "SEC"):

• Registration Statement [No. 333-278584](http://www.sec.gov/Archives/edgar/data/1851194/000119312524090959/d799026ds3.htm), filed with the SEC on April 9, 2024, registering the offering and resale by certain selling stockholders from time to time of up to 11,174,000 shares of the Registrant's common stock, par value $0.0001 per share ("Common Stock") that were sold and issued to the selling stockholders in a private placement pursuant to a stock purchase agreement, dated March 6, 2024.

• Registration Statement [No. 333-283076](http://www.sec.gov/Archives/edgar/data/1851194/000119312524253293/d887389ds3.htm), filed with the SEC on November 7, 2024, registering the offering and resale by a certain selling stockholder from time to time of up to 7,060,100 shares of Common Stock issuable upon conversion of 70,601 shares of Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") by the selling stockholder. The shares of Series A Preferred Stock were sold and issued to the selling stockholders in a private placement pursuant to a stock purchase agreement, dated September 23, 2024.

On March 4, 2026, pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2026, by and among the Registrant, Eli Lilly and Company ("Parent") and RYLS Merger Corporation ("Merger Sub"), Merger Sub merged with and into the Registrant (the "Merger"), with the Registrant continuing as the surviving corporation and becoming a wholly owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Registrant has terminated any and all offerings and sales of securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in each Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities of the Registrant registered under such Registration Statement which remain unsold at the termination of the offering, the Registrant hereby terminates the effectiveness of each Registration Statement and removes from registration all of the securities that remain unsold under each Registration Statement as of the date hereof, if any. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to these Post-Effective Amendments, there will be no remaining securities registered by the Registrant pursuant to the Registration Statements.

The foregoing description of the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as Exhibit 2.1 to the Registrant's Current Report on Form 8-K filed with the SEC on January 7, 2026.

------

**SIGNATURE** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Indianapolis, State of Indiana, on March 4, 2026.

---

| | |
|:---|:---|
| **VENTYX BIOSCIENCES, INC.** | **VENTYX BIOSCIENCES, INC.** |
| By: | /s/ Jonathan R. Haug |
| Name: | Jonathan R. Haug |
| Title: | President |

---

No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.